SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Trading Update

16 Apr 2025 07:00

RNS Number : 1833F
Oxford Instruments PLC
16 April 2025
 

 

 

Oxford Instruments plc

Full-year trading update - 16 April 2025

 

Strong H2 delivered - full-year trading in line with expectations

Good progress on execution of the strategy

 

 

Oxford Instruments plc, a leading provider of scientific technology and expertise to academic and commercial partners, is today issuing a trading update for the year ended 31 March 2025.

 

We have delivered a strong full-year performance, in line with expectations. This has been underpinned by continued momentum in order intake and good progress on the execution of our strategy. We are seeing the benefits of the actions we have taken to drive operational excellence, improve commercial execution, and bring a greater focus on our costs.

 

Revenue growth in the second half has been strong, as anticipated, resulting in full-year revenue growth expected to be around +9% at constant currency1 (+6% at actual rates) versus the prior year. Demand has remained healthy, with 3% year-on-year order growth at constant currency.

 

Full-year adjusted operating profit2 is expected to be up around 13% on a constant currency basis (3% at actual rates), in line with market expectations. Group constant currency adjusted operating margin is expected to be around 17.8% (16.5% at actual rates), up 70 bps year on year with margin progress in both divisions.

 

Our Imaging & Analysis division, which represents two-thirds of Group revenue and around 90% of its operating profit, has performed well, growing both orders and revenue whilst maintaining its excellent operating margin above 24% at constant currency. Semiconductor revenues have grown strongly and, along with materials analysis, have offset continuing softness in the healthcare and life science end market.

 

Our Advanced Technologies division has delivered strong double digit constant currency revenue growth. As anticipated, we delivered a number of large customer orders in our quantum business which, together with operational improvements, resulted in a return to profitability. We have also continued to grow our compound semiconductor business in its new facility and increase our Tier 1 customer base, achieving both double-digit revenue growth and a margin improvement.

Richard Tyson, CEO, commented:

 "I am very pleased with how the team have embraced the strategy, delivering strong results despite the macro volatility seen in H2 and the execution of our pivot away from certain market segments in China."

"We continue to closely monitor and adapt to the potential impacts of macro events. Oxford Instruments' growth and resilience is underpinned by our diversified portfolio of market-leading technologies, deployed in multiple structurally growing sectors across all the major geographies. In addition, there are significant opportunities within our own control, as we accelerate our operational transformation programme, work to simplify and standardise our business, and drive a continued critical focus on product profitability."

Oxford Instruments management will present its full-year results to analysts and investors at Deutsche Numis, 45 Gresham Street, London EC2V 7BF, on 10 June 2025.

 

Notes:

1. Constant currency numbers are prepared on a month-by-month basis using the translational and transactional exchange rates which prevailed in the previous year rather than the actual exchange rates which prevailed in the year. Transactional exchange rates include the effect of our hedging programme.

2. Adjusted items exclude the amortisation and impairment of acquired intangible assets, acquisition items, business reorganisation costs, other significant non‑recurring items, and the mark-to-market movement of financial derivatives.

 

The financial information in this trading update is unaudited.

LEI: 213800J364EZD6UCE231

 

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Head of Investor Relations Stephen.lamacraft@oxinst.com 

 

MHP Group

Katie Hunt/Tim Rowntree/ 07710 117517

Veronica Farah oxfordinstruments@mhpgroup.com

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide with market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductors, and healthcare & life science. Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow. Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress. Founded in 1959 as the first technology business to be spun out from Oxford University, Oxford Instruments is now a global, FTSE250 company listed on the London Stock Exchange (OXIG). For more information, visit www.oxinst.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKPBDFBKDPQD
Date   Source Headline
12th Jun 20269:25 amPRNTransaction in Own Shares
9th Jun 20267:00 amRNSPreliminary Results
1st Jun 20262:03 pmPRNTotal Voting Rights
1st Jun 20261:59 pmPRNIssue of Equity
27th May 20261:58 pmPRNHolding(s) in Company
22nd May 20268:30 amPRNTransaction in Own Shares
14th May 202610:15 amPRNIssue of Equity
8th May 20268:36 amPRNTransaction in Own Shares
1st May 20269:05 amPRNTotal Voting Rights
1st May 20269:00 amPRNTransaction in Own Shares
24th Apr 20268:32 amPRNTransaction in Own Shares
17th Apr 20268:48 amPRNTransaction in Own Shares
14th Apr 202611:07 amPRNHolding(s) in Company
14th Apr 20267:00 amRNSTrading Update
13th Apr 20262:10 pmPRNHolding(s) in Company
13th Apr 20269:15 amPRNHolding(s) in Company
10th Apr 20267:00 amPRNTransaction in Own Shares
7th Apr 202611:11 amPRNTransaction in Own Shares
1st Apr 20263:26 pmPRNHolding(s) in Company
1st Apr 20262:19 pmPRNTotal Voting Rights
30th Mar 20262:54 pmPRNHolding(s) in Company
27th Mar 20268:31 amPRNTransaction in Own Shares
25th Mar 20263:15 pmPRNHolding(s) in Company
20th Mar 20269:00 amPRNTransaction in Own Shares
20th Mar 20268:00 amPRNHolding(s) in Company
17th Mar 202610:00 amPRNHolding(s) in Company
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amPRNTransaction in Own Shares
5th Mar 20262:40 pmPRNHolding(s) in Company
5th Mar 20267:00 amPRNTransaction in Own Shares
4th Mar 20267:00 amPRNTransaction in Own Shares
3rd Mar 20267:00 amPRNTransaction in Own Shares
2nd Mar 202610:38 amPRNTotal Voting Rights
2nd Mar 20267:00 amPRNExtension of Share Buyback Programme
27th Feb 20267:00 amPRNTransaction in Own Shares
26th Feb 20267:00 amPRNTransaction in Own Shares
25th Feb 20267:00 amPRNTransaction in Own Shares
24th Feb 20267:00 amPRNTransaction in Own Shares
23rd Feb 20267:00 amPRNTransaction in Own Shares
20th Feb 20267:00 amPRNTransaction in Own Shares
19th Feb 20267:00 amPRNTransaction in Own Shares
18th Feb 20267:00 amPRNTransaction in Own Shares
17th Feb 20267:00 amPRNTransaction in Own Shares
16th Feb 20267:00 amPRNTransaction in Own Shares
13th Feb 20267:00 amPRNTransaction in Own Shares
12th Feb 20267:00 amPRNTransaction in Own Shares
10th Feb 20267:00 amPRNTransaction in Own Shares
9th Feb 20267:00 amPRNTransaction in Own Shares
6th Feb 20267:00 amPRNTransaction in Own Shares
5th Feb 20267:00 amPRNTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.